LGM
KYMR icon

Logos Global Management’s Kymera Therapeutics KYMR Stock Holding History

Logos Global Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-130,000
Closed -$10.1M – 76
2025
Q4 		$10.1M Sell
130,000
-120,000
-48% -$8.1M 0.61% 42
2025
Q3 		$14.2M Buy
+250,000
New +$11.3M 1.27% 29
2022
Q1 		– Sell
-200,000
Closed -$12.7M – 58
2021
Q4 		$12.7M Buy
+200,000
New +$11.6M 1.31% 23
2021
Q2 		– Sell
-260,920
Closed -$10.1M – 63
2021
Q1 		$10.1M Buy
260,920
+150,000
+135% +$9.03M 0.99% 21
2020
Q4 		$6.88M Sell
110,920
-190,000
-63% -$9.27M 0.59% 33
2020
Q3 		$9.72M Buy
+300,920
New +$9.19M 1.24% 19

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Logos Global Management's KYMR Position: Q1 2026 in Review

Logos Global Management sold out of Kymera Therapeutics (KYMR) in Q1 2026, closing a stake of 130,000 shares — an estimated $10.1M sold.

Logos Global Management first reported a position in KYMR in Q3 2020 and held it in 6 quarters. The position peaked at $14.2M in Q3 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Logos Global Management reported no remaining Kymera Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Logos Global Management sold 130,000 Kymera Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Logos Global Management first reported a position in Kymera Therapeutics in Q3 2020 and held it in 6 quarters.
  • Logos Global Management's Kymera Therapeutics position peaked at $14.2M in Q3 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Logos Global Management's 13F filing for Q1 2026, filed 15 May 2026.